Neuroinflammation in L-DOPA-induced dyskinesia: beyond the immune function

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Neuroinflammation, characterized by reactive microglia and cytokine release, is integral to Parkinson's disease (PD) neuropathology.
• Pro-inflammatory cytokines, notably tumor necrosis factor-alpha (TNF-α), modulate brain functions including neurotransmitter metabolism and plasticity.
• Preclinical models show heightened neuroinflammation in the rat striatum correlating with L-DOPA-induced dyskinesia (LID).

Purpose of the Study:

• To investigate the role of glial cells and their secreted molecules in the non-neuronal mechanisms of LID.
• To review evidence supporting striatal neuroinflammation, focusing on microglia and TNF-α, in LID development.
• To explore how TNF-α influences LID through various cellular and molecular pathways.

Main Methods:

• Review of preclinical studies examining neuroinflammation in Parkinson's disease models.
• Analysis of the involvement of microglia and TNF-α in L-DOPA-induced dyskinesia.
• Discussion of potential mechanisms linking TNF-α to altered neuronal function in LID.

Main Results:

• Striatal neuroinflammation, involving microglia and TNF-α, is exacerbated in parkinsonian rats with LID.
• TNF-α may contribute to LID by affecting receptor trafficking in medium spiny neurons (MSNs).
• TNF-α might also impact dopamine synthesis and serotonin metabolism, contributing to altered neuronal responses in LID.

Conclusions:

• Striatal neuroinflammation, mediated by microglia and TNF-α, plays a significant role in the development of L-DOPA-induced dyskinesia.
• TNF-α presents a potential therapeutic target for mitigating LID by influencing neuronal function, dopamine, and serotonin pathways.
• Targeting glial-secreted cytokines offers a novel therapeutic strategy for preventing or treating L-DOPA-induced dyskinesia in Parkinson's disease.